Updates are available Correction dated 2025-04-23
Click to view Correction: https://doi.org/10.1038/s41586-025-09022-x
-
Authors
Shen, Yinan
Bai, Xueli https://orcid.org/0000-0002-2934-0880
Zhang, Qi
Liang, Xingmei
Jin, Xinyan
Zhao, Zeda
Song, Wei
Tan, Qian
Zhao, Ronghua
Jia, William
Gu, Shanzhi
Shi, Guoming https://orcid.org/0000-0003-3817-9117
Zheng, Ziwei
Wei, Guyue
Wang, Youlei
Fang, Tian
Li, Yuwei
Wang, Zijun
Yang, Zifan
Guo, Sida
Lin, Danni
Wei, Fang
Wang, Lei
Sun, Xiaoli
Qin, Aijun
Xie, Longshen
Qiu, Yeting
Bao, Wenqing
Rahimian, Shah
Singh, Manu https://orcid.org/0000-0001-9396-1502
Murad, Yanal
Shang, Jianying
Chu, Min
Huang, Maoliang
Ding, Jun
Chen, Wei
Ye, Yufu
Chen, Yiwen
Li, Xiang
Liang, Tingbo https://orcid.org/0000-0003-0143-3353
- License Information
-
More Information
Article History
Received: 19 June 2024
Accepted: 30 January 2025
First Online: 19 March 2025
Change Date: 23 April 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-025-09022-x
Competing interests
: CNBG-Virogin Biotech (Shanghai) owns the patent rights for VG161 in mainland China. Virogin Biotech owns the patent rights for VG161 outside mainland China. The authors declare no competing interests.
